Suppr超能文献

腹膜透析相关性腹膜炎:挑战与解决方案

Peritoneal dialysis-related peritonitis: challenges and solutions.

作者信息

Salzer William L

机构信息

School of Medicine, University of Missouri, Columbia, MO, USA.

出版信息

Int J Nephrol Renovasc Dis. 2018 Jun 11;11:173-186. doi: 10.2147/IJNRD.S123618. eCollection 2018.

Abstract

Peritoneal dialysis is an effective treatment modality for patients with end-stage renal disease. The relative use of peritoneal dialysis versus hemodialysis varies widely by country. Data from a 2004 survey reports the percentage of patients with end-stage renal disease treated with peritoneal dialysis to be 5%-10% in economically developed regions like the US and Western Europe to as much as 75% in Mexico. This disparity is probably related to the availability and access to hemodialysis, or in some cases patient preference for peritoneal over hemodialysis. Peritoneal dialysis-related peritonitis remains the major complication and primary challenge to the long-term success of peritoneal dialysis. Fifty years ago, with the advent of the Tenckhoff catheter, patients averaged six episodes of peritonitis per year on peritoneal dialysis. In 2016, the International Society for Peritoneal Dialysis proposed a benchmark of 0.5 episodes of peritonitis per year or one episode every 2 years. Despite the marked reduction in peritonitis over time, peritonitis for the individual patient is problematic. The mortality for an episode of peritonitis is 5% and is a cofactor for mortality in another 16% of affected patients. Prevention of peritonitis and prompt and appropriate management of peritonitis is essential for the long-term success of peritoneal dialysis in all patients. In this review, challenges and solutions are addressed regarding the pathogenesis, clinical features, diagnosis, treatment, and prevention of peritoneal dialysis-related peritonitis from the viewpoint of an infectious disease physician.

摘要

腹膜透析是终末期肾病患者的一种有效治疗方式。腹膜透析与血液透析的相对使用情况在不同国家差异很大。2004年一项调查的数据显示,在美国和西欧等经济发达地区,接受腹膜透析治疗的终末期肾病患者比例为5% - 10%,而在墨西哥这一比例高达75%。这种差异可能与血液透析的可及性有关,或者在某些情况下与患者对腹膜透析优于血液透析的偏好有关。腹膜透析相关腹膜炎仍然是腹膜透析长期成功的主要并发症和主要挑战。五十年前,随着Tenckhoff导管的出现,接受腹膜透析的患者平均每年发生六次腹膜炎。2016年,国际腹膜透析学会提出了每年0.5次腹膜炎发作或每两年一次发作的基准。尽管随着时间的推移腹膜炎明显减少,但对于个体患者来说腹膜炎仍然是个问题。一次腹膜炎发作的死亡率为5%,并且在另外16%的受影响患者中是死亡的一个协同因素。预防腹膜炎以及对腹膜炎进行及时和恰当的管理对于所有患者腹膜透析的长期成功至关重要。在这篇综述中,从传染病医生的角度探讨了腹膜透析相关腹膜炎的发病机制、临床特征、诊断、治疗和预防方面的挑战及解决方案。

相似文献

1
Peritoneal dialysis-related peritonitis: challenges and solutions.腹膜透析相关性腹膜炎:挑战与解决方案
Int J Nephrol Renovasc Dis. 2018 Jun 11;11:173-186. doi: 10.2147/IJNRD.S123618. eCollection 2018.
9
Surgical Complications of Peritoneal Dialysis.腹膜透析的手术并发症
Chirurgia (Bucur). 2018 Sept-Oct;113(5):611-624. doi: 10.21614/chirurgia.113.5.611.

引用本文的文献

本文引用的文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验